- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07659925
Periodization-Based Strength Exercise Training in İndividuals With Type 2 Diabetes (T2DM_NLP)
A Comparison of the Effects of Different Periodization-Based Strength Training Programs in Individuals With Type 2 Diabetes Mellitus
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Type 2 diabetes mellitus is associated with reduced exercise capacity, decreased muscle strength, impaired quality of life, and metabolic dysfunction. Exercise training is recommended as an important component of diabetes management; however, the comparative effectiveness of different strength training periodization approaches remains unclear.
This randomized controlled trial aims to compare the effects of non-linear periodization and linear periodization strength training programs in individuals with type 2 diabetes mellitus. Participants will be randomized into three groups: a non-linear periodization training group, a linear periodization training group, and a control group receiving usual care.
The intervention will be conducted for 8 weeks, three times per week. Outcomes including exercise capacity, muscle strength, body composition, quality of life, and metabolic parameters will be evaluated before and after the intervention period.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Ayşegül Erkoç, PT
- Número de teléfono: +90 553-301-36-73
- Correo electrónico: erkcaysegl@gmail.com
Ubicaciones de estudio
-
-
Ankara
-
Ankara, Ankara, Turquía (Türkiye), 06790
- Reclutamiento
- Baskent University Hospital
-
Contacto:
- Ayşegül Erkoç, PT
- Número de teléfono: +90 553-301-36-73
- Correo electrónico: erkcaysegl@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Adults aged between 18 to 65 years
- Diagnosis of Type 2 Diabetes Mellitus (T2DM)
- Not having participated in any structured exercise program within the last 6 months
- Willingness to participate in the study and provide written informed consent
Exclusion Criteria:
- Presence of nephropathy, retinopathy, or peripheral neuropathy
- Presence of neurological, cognitive, or orthopedic disorders that may affect outcome measurements
- Severe respiratory disease (Forced Expiratory Volume in the first second [FEV1] <35% or Forced Vital Capacity [FVC] <50%)
- Presence of ischemic heart disease or peripheral arterial disease
- History of any cardiovascular event within the last 6 months
- Current malignancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Non-linear Periodization Group
Participants will receive non-linear periodization-based strength training three times per week for 8 weeks.
|
Participants will perform supervised non-linear periodization-based strength training three times per week for 8 weeks.
|
|
Experimental: Linear Periodization Group
Participants will receive linear periodization-based strength training three times per week for 8 weeks.
|
Participants will perform supervised linear periodization-based strength training three times per week for 8 weeks.
|
|
Comparador activo: Control Group
Participants will receive usual care and no structured exercise intervention during the study period.
|
Participants will receive usual care and no structured exercise intervention during the study period.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Exercise Capacity
Periodo de tiempo: Baseline and after 8 week
|
Exercise capacity will be assessed using the 6-Minute Walk Test (6MWT)
|
Baseline and after 8 week
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Peripheral Muscle Strength
Periodo de tiempo: Baseline and after 8 weeks
|
Peripheral muscle strength will be assessed using handheld dynamometry for upper and lower extremity muscle groups and reported in Newton (N).
|
Baseline and after 8 weeks
|
|
Change in Hand Grip Strength
Periodo de tiempo: Baseline and after 8 weeks
|
Hand grip strength will be assessed using a hand dynamometer and reported in kilograms (kg).
|
Baseline and after 8 weeks
|
|
Change in Diabetes Quality of Life Questionnaire Score
Periodo de tiempo: Baseline and after 8 weeks
|
Change in the Turkish version of the Diabetes Quality of Life Questionnaire (DQOL) total score and subscale scores from baseline to 8 weeks will be evaluated.
The DQOL consists of 45 items assessing treatment satisfaction, psychological impact, concerns about future effects of diabetes, and social/vocational concerns.
Each item is scored on a 1-5 scale, and higher scores indicate better diabetes-related quality of life.
|
Baseline and after 8 weeks
|
|
Change in Body Fat Percentage
Periodo de tiempo: Baseline and after 8 weeks
|
Body fat percentage (%) will be assessed using bioelectrical impedance analysis (BIA).
|
Baseline and after 8 weeks
|
|
Change in Skeletal Muscle Mass
Periodo de tiempo: Baseline and after 8 weeks
|
Skeletal muscle mass (kg) will be assessed using bioelectrical impedance analysis (BIA).
|
Baseline and after 8 weeks
|
|
Change in Resting Metabolic Rate
Periodo de tiempo: Baseline and after 8 weeks
|
Resting metabolic rate (kcal/day) will be assessed using indirect calorimetry (COSMED Fitmate Pro, Rome, Italy).
|
Baseline and after 8 weeks
|
|
Change in Hemoglobin A1c (HbA1c)
Periodo de tiempo: Baseline and after 8 weeks
|
Glycemic control will be assessed by measuring glycated hemoglobin (HbA1c) levels (%).
|
Baseline and after 8 weeks
|
|
Change in Fasting Blood Glucose
Periodo de tiempo: Baseline and after 8 weeks
|
Glycemic control will be assessed by measuring fasting blood glucose levels (mg/dL).
|
Baseline and after 8 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Neslihan Duruturk, PhD, Baskent University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- T2DM-NLP-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .